Business
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
TOULOUSE, France & FULLERTON, Calif. & LISSES, France, November 20, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, and SEBIA, a global player in specialized biological diagnostics, today announced an exclusive global strategic partnership in sepsis.
About this update from Abionyx Pharma Sa
[{"type":"text","content":"TOULOUSE, France & FULLERTON, Calif. & LISSES, France, November 20, 2025--(BUSINESS WIRE)--Regulatory News:","length":115,"tagName":"p"},{"type":"text","content":"ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, and SEBIA, a global player in specialized biological diagnostics, today announced an exclusive global strategic partnership in sepsis.","length":347,"tagName":"p"},{"type":"text","content":"New tests for early diagnosis and monitoring of sepsis treatment","length":64,"tagName":"p"},{"type":"text","content":"This partnership will enable the validation of new infectious and metabolic diagnostic tests that allow for earlier and more accurate identification of the severity of sepsis, enabling faster treatment and dynamic monitoring of treatment efficacy, including ABIONYX Pharma's recombinant apoA-I.","length":298,"tagName":"p"},{"type":"text","content":"A global partnership based on scientific excellence and technological complementarity","length":85,"tagName":"p"},{"type":"text","content":"Under this agreement, SEBIA will draw on its unique expertise in preparative analytical chemistry for blood samples and in the development and validation of methods for separating proteins, lipoproteins, and glycoproteins. ABIONYX Pharma, for its part, will contribute its expertise in lipid biology and clinical studies, and its in-depth understanding of sepsis acquired through its recombinant biomedicine in phase 2b/3.","length":422,"tagName":"p"},{"type":"text","content":"The two companies have established a Joint Steering Committee to jointly oversee the program, from initial analytical validations to regulatory approvals.","length":154,"tagName":"p"},{"type":"text","content":"A confidentiality framework necessary for exclusive cooperation","length":63,"tagName":"p"},{"type":"text","content":"Discussions between the two companies, which began several months ago, have led to an extensive and exclusive cooperation agreement. The financial terms, technical milestones, and deployment conditions remain confidential.","length":222,"tagName":"p"},{"type":"text","content":"A major medical and economic challenge","length":38,"tagName":"p"},{"type":"text","content":"Every ...